Stargardt Disease Pipeline Analysis, Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Treatment Market, Therapies, MOA, ROA, Companies by DelveInsight

(Albany, USA) DelveInsight's, "Stargardt Disease Pipeline Insight" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Stargardt Disease (STGD) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Stargardt Disease Pipeline. Dive into DelveInsight's comprehensive report today! @ Stargardt Disease Pipeline Outlook- https://www.delveinsight.com/sample-request/stress-urinary-incontinence-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Key Takeaways from the Stargardt Disease Pipeline Report
• In October 2024:- Astellas Pharma- A Phase 2b Randomized, Double-masked, Controlled Trial to Establish the Safety and Efficacy of Zimura™ (Complement C5 Inhibitor) Compared to Sham in Subjects With Autosomal Recessive Stargardt Disease. The purpose of this study is to evaluate the safety and efficacy of avacincaptad pegol intravitreal injection compared to Sham in participants with autosomal recessive Stargardt disease 1 (STGD1).
• In October 2024:- Ascidian Therapeutics, Inc- This study is an open-label, single ascending dose clinical trial in participants who have ABCA4-related retinopathies. This is the first-in-human clinical trial in which ACDN-01 will be evaluated for safety, tolerability, and preliminary efficacy following a single subretinal injection of ACDN-01.
• DelveInsight's Stargardt Disease pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for Stargardt Disease treatment.
• The leading Stargardt Disease Companies such as Innovacell Biotechnologie GmbH, Versameb AG, Taiho Pharmaceutical, Cook MyoSite, Mapi Pharmaand others.
• Promising Stargardt Disease Therapies such as OCU410ST, Tinlarebant, ALK-001, ACDN-01, avacincaptad pegol, and others.

Stay ahead with the most recent pipeline outlook for Stargardt Disease. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Stargardt Disease Treatment Drugs- https://www.delveinsight.com/sample-request/stress-urinary-incontinence-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Stargardt Disease Emerging Drugs Profile
• ICES13: Innovacell Biotechnologie GmbH
ICES13 is made from autologous skeletal muscle cells that have been isolated from a muscle biopsy and reproduced in a laboratory. The goal is to treat the cause of the stress urinary incontinence by subsequently injecting ICES13 into the sphincter muscle of the affected person. The drug is currently being evaluated under Phase III clinical trial for the treatment of patients with Stress Urinary Incontinence.
• VMB-100: Versameb AG
VMB-100 is an intramuscularly locally delivered, sequence engineered messenger ribonucleic acid (mRNA) encoding for human insulin-like growth factor-1 (IGF-1) under investigation for the treatment of stress urinary incontinence (SUI). VMB-100 has the potential to become first-and best-in-class in sustained muscle regeneration following short-term treatment. The drug is currently in the preclinical stage of development for the treatment of patients with Stress Urinary Incontinence.

Explore groundbreaking therapies and clinical trials in the Stargardt Disease Pipeline. Access DelveInsight's detailed report now! @ New Stargardt Disease Drugs- https://www.delveinsight.com/sample-request/stress-urinary-incontinence-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Stargardt Disease Companies
Innovacell Biotechnologie GmbH, Versameb AG, Taiho Pharmaceutical, Cook MyoSite, Mapi Pharmaand others.

Stress Urinary Incontinence pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Intravenous
• Subcutaneous
• Oral
• Intramuscular

Stargardt Disease Products have been categorized under various Molecule types such as
• Monoclonal antibody
• Small molecule
• Peptide

Unveil the future of Stargardt Disease Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Stargardt Disease Market Drivers and Barriers- https://www.delveinsight.com/sample-request/stress-urinary-incontinence-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Scope of the Stargardt Disease Pipeline Report
• Coverage- Global
• Stargardt Disease Companies- Innovacell Biotechnologie GmbH, Versameb AG, Taiho Pharmaceutical, Cook MyoSite, Mapi Pharmaand others.
• Stargardt Disease Therapies- OCU410ST, Tinlarebant, ALK-001, ACDN-01, avacincaptad pegol, and others.
• Stargardt Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Stargardt Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Stargardt Disease Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Stargardt Disease Companies, Key Products and Unmet Needs- https://www.delveinsight.com/sample-request/stress-urinary-incontinence-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Content
1. Introduction
2. Executive Summary
3. Stargardt Disease: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Stargardt disease - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Tinlarebant: Belite Bio
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. KIO-301: Kiora Pharmaceuticals
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. OCU410: Ocugen
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Stargardt disease Key Companies
21. Stargardt disease Key Products
22. Stargardt disease -Unmet Needs
23. Stargardt disease -Market Drivers and Barriers
24. Stargardt disease -Future Perspectives and Conclusion
25. Stargardt disease Analyst Views
26. Stargardt disease Key Companies
27. Appendix

Trending Reports:
• Healthcare Partner Identification Services: https://www.delveinsight.com/consulting/partner-identification-services
• Cardiorenal Syndrome Market: https://www.delveinsight.com/report-store/cardiorenal-syndrome-market
• Vascular Access Devices Market: https://www.delveinsight.com/report-store/vascular-access-device-market
• Cerebral Vein Thrombosis Market: https://www.delveinsight.com/report-store/deep-vein-thrombosis-market
• Dermal Erythema Market: https://www.delveinsight.com/sample-request/dermal-erythema-market
• Polypoidal Choroidal Vasculopathy Market: https://www.delveinsight.com/sample-request/polypoidal-choroidal-vasculopathy-market
• Bone Densitometers Market: https://www.delveinsight.com/blog/bone-densitometers-market-analysis
• Intracranial Pressure Monitoring Devices Market: https://www.delveinsight.com/report-store/intracranial-pressure-monitoring-devices-market
• Acoustic Neuroma Market: https://www.delveinsight.com/report-store/acoustic-neuroma-market
• Neurovascular Devices Market: https://www.delveinsight.com/report-store/neurovascular-thrombectomy-devices-market
• Ophthalmic Imaging Equipment Market: https://www.delveinsight.com/report-store/ophthalmic-imaging-equipment-market
• Neurostimulation Devices Market: https://www.delveinsight.com/report-store/neurostimulation-devices-market
• Radioligand Therapies Market: https://www.delveinsight.com/report-store/radioligand-therapies-market-forecast
• Alopecia Areata Market: https://www.delveinsight.com/report-store/alopecia-areata-market
• Brain Aneurysm Stents Market: https://www.delveinsight.com/report-store/intracranial-stents-market
• Necrotizing Enterocolitis Market: https://www.delveinsight.com/report-store/necrotizing-enterocolitis-market
• Angioedema Market: https://www.delveinsight.com/report-store/hereditary-angioedema-market
• Arthroscopic Shavers Market: https://www.delveinsight.com/report-store/arthroscopic-shavers-market
• Automated External Defibrillators Market: https://www.delveinsight.com/report-store/external-defibrillators-market
• Catheter-related Bloodstream Infections Market: https://www.delveinsight.com/report-store/catheter-related-bloodstream-infection-market
• Chronic Hepatitis B Virus Market: https://www.delveinsight.com/report-store/chronic-hepatitis-b-virus-market
• Fuchs Dystrophy Market: https://www.delveinsight.com/report-store/fuchs-endothelial-corneal-dystrophy-fecd-market
• Hearing Implants Market: https://www.delveinsight.com/report-store/hearing-implants-market
• Non Alcoholic Fatty Liver Disease Nafld Market: https://www.delveinsight.com/report-store/non-alcoholic-fatty-liver-disease-nafld-market
• Xerostomia Market: https://www.delveinsight.com/report-store/xerostomia-market

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting/r-and-d-analysis
Case study: https://www.delveinsight.com/case-study/esmo-conference-coverage-gastrointestinal-cancers

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.